

Palliative Squamous Cell Cancer Regimens

The following table lists the evidence-informed regimens (both IV and non-IV) for Squamous cell cancer used in the palliative setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors.

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

Squamous Cell Cancer	
Regimen Code	Regimen Abstract
CISP	CISplatin 50-75 mg/m ² IV day 1. Q21 days
CISP(RT)	CISplatin 100 mg/m ² IV day 1 Concurrent with radiotherapy Q21 days
CISP(RT-W)	CISplatin 40 mg/m ² IV weekly Concurrent with radiotherapy
CISPFU	CISplatin 100 mg/m ² IV day 1; Fluorouracil 1000 mg/m ² /day CIV over 4 days. Q21 days
CRBP(RT)	CARBOplatin AUC 1.5 IV day 1 weekly Concurrent with radiotherapy
CRBPFU	CARBOplatin AUC 5 IV day 1; Fluorouracil 1000 mg/m ² /d CIV days 1-4. Q21 days
CETU	<i>Cycle 1:</i> Cetuximab 400 mg/m² IV – not currently publicly funded for the regimen and treatment intent <i>Subsequent cycles:</i> Cetuximab 250 mg/m² IV weekly – not currently publicly funded for the regimen and treatment intent Q7 days